Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue in the sugar business declined due to lower selling prices following the price revision, while profit increased due to lower costs including raw sugar procurement and manufacturing costs. Profit in the bio business declined due to higher raw materials and other costs.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥16,598 million (YoY -0.4%) |
| Operating profit | ¥1,623 million (YoY +12.0%) |
| Ordinary income | ¥1,716 million (YoY +9.4%) |
| Profit attributable to owners of the parent | ¥1,176 million (YoY -22.4%) |
| Net income per share | ¥42.74 |
| Equity ratio | End of the current fiscal period 66.9 / End of previous period 64.8 |
| Total assets | ¥34,850 million |
| Net assets | ¥23,309 million |
| Cash flows from operating activities | ¥1,354 million |
| Cash flows from investing activities | ¥-353 million |
| Cash flows from financing activities | ¥-1,022 million |
| Cash and cash equivalents at end of period | ¥2,866 million |
| Full-year earnings forecast | Net Sales ¥32,100 million (YoY -2.7%) / Operating profit ¥2,400 million (YoY -21.3%) / Ordinary income ¥2,600 million (YoY -22.1%) / Net income ¥1,800 million (YoY -34.9%) |
| Annual Dividend Forecast | ¥20 → ¥16（-20.0%） |
| Segment revenue | Sugar business ¥15,765 million (YoY -0.4%), Biotechnology Business ¥847 million (YoY 0.0%), Other ¥71 million (YoY +4.0%) |
| Segment profit | Sugar business ¥2,144 million (YoY +8.7%), Biotechnology Business ¥149 million (YoY -6.9%), Other ¥39 million (YoY +2.5%) |
| Depreciation and amortization | ¥304 million |
| Breakdown of extraordinary income (loss) | Extraordinary income: None (-); extraordinary loss: None recognized |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 35,000,000 shares |
| Treasury Shares at Period-End | 7,409,346 shares |
| Factors Behind Changes in Business Performance | Revenue in the sugar business declined due to lower selling prices following the price revision, while profit increased due to lower costs including raw sugar procurement and manufacturing costs. Profit in the bio business declined due to higher raw materials and other costs. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the sugar business, revenue declined due to lower selling prices following the price revision in November of the previous year, but profit increased as a result of efforts to reduce costs including raw sugar procurement and manufacturing costs. In the bio business, segment profit declined due to higher raw materials and other costs.